Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Improvement of Live Babies Rates After ICSI, Using cpFT
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 366
- Registration Number
- NCT04954274
- Locations
- 🇫🇷
Department Biology of Reproduction, Hospital Cochin AP-HP, Paris, France
Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT04894188
- Locations
- 🇨🇳
National Taiwan University Hospital Yunlin Branch, Douliu City/Huwei Township, Yunlin County, Taiwan
🇨🇳National Taiwan University Hospital, Tapiei, Taiwan
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT04862143
- Locations
- 🇸🇪
Novartis Investigative Site, Orebro, Sweden
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04736108
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Conditions
- Stage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
- Interventions
- Other: Questionnaire Administration
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT04734730
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
- Conditions
- Neuroendocrine TumorsCarcinoid SyndromeDiarrhea
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Chandrikha Chandrasekhara
- Registration Number
- NCT04713202
- Locations
- 🇺🇸
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT04563936
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
- Conditions
- Invasive Lobular Breast CarcinomaER+ Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 65
- Registration Number
- NCT04551495
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇫🇷Institut Bergonié, Bordeaux, France
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 80
- Registration Number
- NCT04536467
- Locations
- 🇪🇬
Beni Suef university, Fayoum, Mesala, Egypt
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ElastographyProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2753
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Sands Cancer Center, Canandaigua, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.